- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about NVS
Recent news which mentions NVS
A Look Into Healthcare Sector Value Stocks
October 24, 2022
From Benzinga
Novartis Experimental Drug Shows Meaningful Superiority Over Previous Treatment In Rare Blood Disorder
October 24, 2022
Tickers
NVS
From Benzinga
Novartis hemoglobinuria trial meets two primary endpoints
October 24, 2022
Tickers
NVS
From MarketWatch
Precision Medicine Could Get Even More Precise With Allarity Therapeutics' "Next-Generation" Diagnostics Platform
October 17, 2022
From Benzinga
Biden Asked OPEC+ To Delay Output Decision, Elon Musk Faces Federal Probe Over Twitter Deal, Netflix Ad-Supported Plan: Top Stories Friday, Oct. 14
October 14, 2022
From Benzinga
Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug
October 14, 2022
From Benzinga
From Benzinga
2 Cathie Wood Stocks That Are Beating the Market This Year
October 07, 2022
From Motley Fool
Got $5,000? These 2 Stocks Are Bargain Buys Right Now
October 06, 2022
From Motley Fool
Could This Biosimilar Drug Candidate Be a Hit for Novartis?
October 03, 2022
From Motley Fool
Why Moderna Was a Sickly Stock Today
September 29, 2022
From Motley Fool
Is Biogen a Smart Biotech Stock to Buy Right Now?
September 29, 2022
From Motley Fool
European Drug Makers Say Higher Energy Costs Eating Margins: Report
September 27, 2022
From Benzinga
Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings
September 23, 2022
From Benzinga
From Benzinga
7 Safe Havens All Investors Should Have Exposure to in 2022
September 22, 2022
From InvestorPlace
Novartis Unveils New Strategy Focused On US-First, Eight Blockbuster Brands
September 22, 2022
Tickers
NVS
From Benzinga
3 Highly Profitable Stocks That Are Super Cheap Right Now
September 21, 2022
From Motley Fool
From Benzinga
Novartis To Petition US Supreme Court To Uphold Patent Validity For Multiple Sclerosis Drug, Gilenya
September 21, 2022
Tickers
NVS
From Benzinga
3 Stocks That Could Rocket on Biden’s Cancer Moonshot
September 20, 2022
From InvestorPlace
5 Value Stocks In The Healthcare Sector
September 19, 2022
From Benzinga
From Benzinga
Swiss Competition Commission Investigates Novartis' Patent Use To Fend Off Competition
September 15, 2022
Tickers
NVS
From Benzinga
Novartis says authorities investigating a patent assertion
September 15, 2022
Tickers
NVS
From MarketWatch
Novartis Dodges Whistleblower Lawsuit Regarding Multiple Sclerosis Drug Kickback Claims
September 14, 2022
Tickers
NVS
From Benzinga
From Benzinga
Novartis' Cosentyx Shows To Ease Symptoms In Painful Skin Condition
September 12, 2022
Tickers
NVS
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.